PMID- 25503133 OWN - NLM STAT- MEDLINE DCOM- 20150324 LR - 20210208 IS - 1791-7530 (Electronic) IS - 0250-7005 (Linking) VI - 34 IP - 12 DP - 2014 Dec TI - Incomplete epithelial-mesenchymal transition in p16-positive squamous cell carcinoma cells correlates with beta-catenin expression. PG - 7061-9 AB - BACKGROUND: The epithelial-mesenchymal transition (EMT) is suggested to be a crucial factor for the development of an invasive and metastatic cell phenotype, which is characterized by down-regulation of epithelial adhesive proteins (e.g. E-cadherin) and induction of mesenchymal proteins (e.g. vimentin). Therefore, there is a great clinical interest to specify this phenotype. Different growth factors induce EMT, such as epithelial growth factor (EGF) and transforming growth factor beta 1 (TGFbeta1). The role of EMT in human papilloma virus (HPV)-positive squamous cell carcinoma (SCC) is still not understood. The aim of this study was to investigate the expression pattern in p16-positive and -negative SCC cells of vimentin, beta-catenin and E-cadherin after stimulation with growth factors. MATERIALS AND METHODS: We incubated the p16-positive CERV196 and p16-negative HNSCC22B SCC cell lines with EGF and EGF/TGFbeta1 (10 ng/ml) and detected E-cadherin, vimentin and beta-catenin by immunocytochemistry and enzyme-linked immunosorbent assay after 5, 24 and 96 h. RESULTS: We found a low expression of vimentin in all studied tumor cell lines. The negative control of HNSCC22B cells showed a higher intrinsic level of membranous E-cadherin and beta-catenin. We found statistically significant EGF/TGFbeta1-induced expression of vimentin dependent on incubation time in p16-negative HNSCC22B cells. Particularly in the presence of EGF, we detected an increase of beta-catenin and vimentin expression in p16-positive SCC tumor cell lines in addition to induced cell scattering and unexpected expression of E-cadherin. CONCLUSION: In conclusion, E-cadherin, beta-catenin and vimentin expression are important features to characterize EMT-like events. We were able to show incomplete EGF-induced EMT with beta-catenin expression in p16-positive SCC. Extended studies are required to investigate the mechanistic role of EMT markers, especially in p16-positive SCC, in order to develop new anti-SCC therapies to block EMT progression. CI - Copyright(c) 2014 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved. FAU - Umbreit, Claudia AU - Umbreit C AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany claudia.umbreit@umm.de. FAU - Flanjak, Julia AU - Flanjak J AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Weiss, Christel AU - Weiss C AD - Institute of Medical Statistics and Biometry, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Erben, Philipp AU - Erben P AD - Department of Urology, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Aderhold, Christoph AU - Aderhold C AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Faber, Anne AU - Faber A AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Stern-Straeter, Jens AU - Stern-Straeter J AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Hoermann, Karl AU - Hoermann K AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. FAU - Schultz, Johannes David AU - Schultz JD AD - Department of Otorhinolaryngology, Head and Neck Surgery, University Medical Centre Mannheim, Medical Faculty Mannheim, University of Heidelberg, Mannheim, Germany. LA - eng PT - Journal Article PL - Greece TA - Anticancer Res JT - Anticancer research JID - 8102988 RN - 0 (Biomarkers, Tumor) RN - 0 (CDKN2A protein, human) RN - 0 (Cadherins) RN - 0 (Cyclin-Dependent Kinase Inhibitor p16) RN - 0 (Neoplasm Proteins) RN - 0 (Transforming Growth Factor beta1) RN - 0 (Vimentin) RN - 0 (beta Catenin) RN - 62229-50-9 (Epidermal Growth Factor) SB - IM MH - Biomarkers, Tumor/*biosynthesis MH - Cadherins/biosynthesis MH - Carcinoma, Squamous Cell/*pathology MH - Cell Adhesion/genetics MH - Cell Line, Tumor MH - Cyclin-Dependent Kinase Inhibitor p16 MH - Enzyme-Linked Immunosorbent Assay MH - Epidermal Growth Factor/pharmacology MH - Epithelial-Mesenchymal Transition/*genetics MH - Gene Expression Regulation, Neoplastic MH - Head and Neck Neoplasms/*pathology MH - Humans MH - Immunohistochemistry MH - Neoplasm Proteins/biosynthesis/*genetics MH - Squamous Cell Carcinoma of Head and Neck MH - Transforming Growth Factor beta1/pharmacology MH - Vimentin/biosynthesis MH - beta Catenin/*biosynthesis OTO - NOTNLM OT - E-cadherin OT - ECM OT - EGF OT - EMT OT - Epithelial growth factor OT - HNSCC OT - HPV OT - SCC OT - TGFbeta1 OT - epithelial-mesenchymal transition OT - extracellular matrix OT - head and neck squamous cell carcinoma OT - human papillomavirus OT - p16-positive SCC OT - squamous cell cancer OT - transforming growth factor beta1 OT - vimentin OT - beta-catenin EDAT- 2014/12/17 06:00 MHDA- 2015/03/25 06:00 CRDT- 2014/12/16 06:00 PHST- 2014/12/16 06:00 [entrez] PHST- 2014/12/17 06:00 [pubmed] PHST- 2015/03/25 06:00 [medline] AID - 34/12/7061 [pii] PST - ppublish SO - Anticancer Res. 2014 Dec;34(12):7061-9.